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Introduction {#sec004}
============

Dengue virus (DENV) is a globally distributed flavivirus with nearly 400 million estimated annual infections and a growing geographic distribution and disease burden \[[@pntd.0005194.ref001]--[@pntd.0005194.ref003]\]. DENV has a historic presence in the Middle East and North Africa (MENA), with outbreaks of dengue and dengue-like disease reported across much of the Eastern Mediterranean region in the 19^th^ and early 20^th^ centuries \[[@pntd.0005194.ref004], [@pntd.0005194.ref005]\]. Today, DENV may be resurging in the MENA \[[@pntd.0005194.ref006], [@pntd.0005194.ref007]\], with recent outbreaks of unprecedented or previously unrecognized magnitude occurring in the Arabian Peninsula and Pakistan \[[@pntd.0005194.ref008], [@pntd.0005194.ref009]\], and a 2015 outbreak in Egypt that occurred following a decades-long absence of reported cases from that country \[[@pntd.0005194.ref010]\]. Still, despite increasing global concern about the threat of *Aedes*-transmitted arboviruses, the epidemiology of DENV in the MENA region remains largely uncharacterized.

Understanding the epidemiology of DENV in the MENA represents an ongoing challenge for multiple reasons \[[@pntd.0005194.ref011]\]. Inadequate human and vector surveillance, non-reporting of illness syndromes, and poor diagnostic capacity limit DENV detection in many countries, resulting in delays in outbreak recognition and sparse data with which to estimate disease burden and infection rates \[[@pntd.0005194.ref012]--[@pntd.0005194.ref014]\]. Case series, outbreak reports, and national notification reports, which contribute much to the epidemiologic knowledge of DENV, may also contain bias in reflecting only those areas with sufficient capacity to detect and report DENV when it occurs \[[@pntd.0005194.ref001]\]. Moreover, clinical diagnosis of DENV infection in the absence of laboratory confirmation is often unreliable \[[@pntd.0005194.ref012], [@pntd.0005194.ref015]--[@pntd.0005194.ref018]\]. Cross-sectional serologic surveys for DENV exposure have the potential to shed light on the broader population burden of DENV without these biases. However, serologic cross-reactions among antibody-based assays for flaviviruses can limit the reliability of such studies in the absence of confirmatory testing, though the latter is difficult to perform and often unavailable \[[@pntd.0005194.ref019], [@pntd.0005194.ref020]\].

To further the knowledge of the epidemiology of DENV in the MENA, we undertook a comprehensive summary and appraisal of published DENV prevalence, incidence, vector infection rates, reported outbreaks, and *Aedes* occurrence reports in the MENA region. This report aims to enhance the understanding of the epidemiology of DENV in the MENA while informing priorities for future research.

Materials and Methods {#sec005}
=====================

Objectives {#sec006}
----------

The objective of this study was to characterize the epidemiology of DENV in the MENA region through a systematic review of human prevalence and incidence studies and infection rates in *Aedes* mosquitoes. We also aimed to summarize reported human outbreaks and *Ae*. *aegypti and Ae*. *albopictus* occurrence in the region. The original search was last updated on December 9, 2015.

Eligibility criteria {#sec007}
--------------------

[Table 1](#pntd.0005194.t001){ref-type="table"} displays the eligibility criteria. In brief, studies containing primary prevalence, incidence, and vector infection rates for DENV in the MENA region were considered eligible for the systematic review. Publication year was not considered an inclusion criterion, as we reasoned that the historic distribution of DENV could be useful in understanding its current epidemiology by depicting ecologically viable regions in which DENV transmission continues to occur or could re-emerge. For incidence studies, those that reported the number of acute infections or seroconversions over any time interval were eligible. Vector infection rate studies were included if they contained a measure of the estimated proportion of infected *Ae*. *aegypti* or *Ae*. *albopictus* at a given time and setting in the MENA region.

10.1371/journal.pntd.0005194.t001

###### Criteria for study inclusion or exclusion.

![](pntd.0005194.t001){#pntd.0005194.t001g}

  **Study type**                    **Inclusion Criteria**                                                                                                                                   **Exclusion Criteria**
  --------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Human prevalence/incidence                                                                                                                                                                 
      publication characteristics   Full article or abstract published in any year, language, setting, or population in the MENA region; any seroconversion interval for incidence studies   Case reports, case series, editorials, letters to editors, reviews, commentaries, qualitative studies, basic science research studies, studies from countries outside the MENA region
      study design                  Any randomized or non-randomized design                                                                                                                  Non-empirical research/modelled data
      outcomes                      DENV seroprevalence or prevalence of laboratory-confirmed infection; DENV incidence (by any laboratory method)                                           No human prevalence or incidence measure reported
  Vector infection rate             Reported *Ae*. *aegypti* or *Ae*. *albopictus* infection rates by any laboratory method                                                                  Basic science research studies, infection rates in other mosquito species or non-MENA country

Outcomes {#sec008}
--------

For the systematic review, the primary outcomes were DENV human prevalence, incidence, and vector infection rates in the MENA region. Secondary outcomes were reports of dengue outbreaks and vector occurrence.

Data sources and search strategy {#sec009}
--------------------------------

We conducted a systematic search for DENV in the MENA following Cochrane Collaboration guidelines \[[@pntd.0005194.ref021]\] and reported our findings using the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) guidelines \[[@pntd.0005194.ref022]\]. The PRISMA checklist is found in [S1 Fig](#pntd.0005194.s001){ref-type="supplementary-material"} and our search criteria in [S2 Fig](#pntd.0005194.s002){ref-type="supplementary-material"}. Briefly, we searched PubMed, Embase, the World Health Organization (WHO) Index Medicus for the Eastern Mediterranean Region and WHO African Index Medicus without publication date or language restrictions, using text and MeSH/Emtree terms exploded to include all subheadings. Our review covered the 23 countries included in the MENA definitions of the WHO/EMRO, World Bank, and the Joint United Nations Programme on HIV/AIDS (UNAIDS) for consistency with earlier regional analyses of various infectious diseases including HIV \[[@pntd.0005194.ref023]\].

Study selection {#sec010}
---------------

For each search, titles and abstracts were imported into Endnote (Thompson Reuters, Philadelphia, PA, USA), duplicates were removed, and were screened by one author (JH) with potential eligibility determined by consensus with a second author (NC) when eligibility was unclear. Full texts of potentially relevant records were retrieved and assessed for eligibility, contacting the author of the report as necessary. Reference lists of all potentially eligible articles and reviews were also searched. In this study, 'report' refers to the document (paper, abstract, or public health record) containing an outcome measure of interest, while 'study' refers to the outcome measure(s) within that report. Hence, reports could contribute more than one study, though multiple reports of the same study were counted only once.

Data Extraction and Synthesis {#sec011}
-----------------------------

Data were extracted by one of the authors (JH) using a pre-piloted data extraction form and entered into a database created in Microsoft Access. Data from reports in English were extracted from the full texts, while reports in French (n = 6), Turkish (n = 3), Dutch (n = 1), and German (n = 1) were extracted from the abstracts and full texts with the help of online language software and French, Turkish, and German language speakers \[[@pntd.0005194.ref024]\]. There were no records in other languages. Studies were compiled by country and organized by year, using separate tables for human prevalence, incidence, and vector infection rates. Prevalence studies were further stratified as follows: 1) *general prevalence studies* measuring the prevalence of anti-DENV antibodies among populations without acute infection (e.g. DENV exposure); and 2) *acute DENV infection studies* assessing the prevalence of laboratory-confirmed DENV infection in those with a) undifferentiated acute febrile illness (AFI) and b) suspected DENV infection ([Table 2](#pntd.0005194.t002){ref-type="table"}). These stratifications were made because of the different study aims and probabilities of having laboratory evidence of DENV infection in each of these populations. Finally, the geographic distribution of all included prevalence studies were mapped according to the first-level administrative division (e.g. state, province) in which each study was conducted (Tableau Software, Seattle, WA, USA).

10.1371/journal.pntd.0005194.t002

###### Definitions of human prevalence study populations identified through the systematic review.
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  **Study Population**   **Definition**
  ---------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  General prevalence     Seroprevalence studies reporting anti-DENV IgG prevalence measures among individuals not suspected to have acute dengue infection, including community members, blood donors, military, students, and hospitalized patients and outpatients receiving care for non-febrile illnesses.
  Acute DENV infection   ***Undifferentiated acute febrile illness (AFI)***: studies for which acute dengue infection is not differentiated by clinical grounds alone; IgG prevalence measures obtained during the acute phase of illness is these studies are presumed to reflect secondary infection.
                         ***Suspected dengue infection***: studies in which defined or undefined clinical criteria for probable dengue infection is stated as an inclusion criterion in the study.

Risk of bias assessment {#sec012}
-----------------------

In order to gain a better understanding of the quality of prevalence studies identified through the systematic review, the risk of bias (ROB) was assessed for each study based on the Cochrane approach \[[@pntd.0005194.ref025]\] and by evaluating the precision of the reported measures. The methodology for this assessment is similar to that which we have previously developed for reviews of HIV and hepatitis C prevalence in the MENA region \[[@pntd.0005194.ref026]--[@pntd.0005194.ref028]\]. Each DENV prevalence measure was considered to have a low, high, or unclear ROB in three domains: sampling methodology, DENV infection ascertainment, and response rate. The latter was defined as the number of tested individuals divided by the number of persons invited to participate in the study \[[@pntd.0005194.ref029]\]. ROB was considered low if (1) sampling was probability-based (i.e. using some form of random selection), (2) DENV prevalence measures included viral neutralization testing (VNT) for general prevalence studies or biological assays (i.e. cell culture, PCR, and NS1 ELISA) for acute infection studies, and (3) response rate was ≥80%. Studies with missing information for any of the domains were classified as having unclear ROB for that specific domain. Sampling strategy was not evaluated for acute infection studies because these studies enrolled individuals presenting to a health facility with acute infection, hence, no population-based sampling is needed to capture this population. Studies were considered to have high precision if the number of individuals tested was ≥ 100. We considered this to be a reasonably sensitive cutoff for precision given the heterogeneous epidemiology of DENV across the region (e.g. a prevalence of 1% entails a 95% CI of 0--3%).

DENV outbreaks and *Aedes* distribution {#sec013}
---------------------------------------

To supplement the epidemiologic data gathered through the systematic search, reported outbreaks and *Ae*. *aegypti* or *Ae*. *albopictus* occurrence in the MENA were also sought from the articles retrieved through the search databases as well as through ProMED-MENA and Google Scholar. Given that the characteristics and definitions of dengue outbreaks in the literature are implicitly variable and that there is currently no consensus on how to define such events \[[@pntd.0005194.ref030]\], we broadly included any outbreak report if the author of the report defined the event as an outbreak. Multiple reports of the same outbreak were recorded only once. We manually marked the location of reported outbreaks on the map as well, designating one mark per each first-level administrative division in which one or more outbreaks were identified. In a separate map, we mapped the country-level occurrence of *Ae*. *aegypti* and *Ae*. *albopictus* in order to further inform the existing or potential epidemiology of DENV in the MENA.

Results {#sec014}
=======

Search results {#sec015}
--------------

The selection process based on PRISMA guidelines is illustrated in [Fig 1](#pntd.0005194.g001){ref-type="fig"} \[[@pntd.0005194.ref022]\]. Briefly, the DENV search yielded 1,258 citations, 91 of which were ultimately eligible for inclusion in the study following the addition of 4 reports identified from the bibliographies of relevant reports and reviews. Four studies from the 1970-80s were excluded that contained DENV seroprevalence of 0--11% in wild and domestic animals in Pakistan, Tunisia, and Turkey, though these may have represented cross-reactions with other flaviviruses \[[@pntd.0005194.ref031]--[@pntd.0005194.ref034]\].

![PRISMA flow diagram of article selection.\
Flow diagram for dengue prevalence, incidence, and vector infection rates in the Middle East and North Africa.](pntd.0005194.g001){#pntd.0005194.g001}

Characteristics of included studies {#sec016}
-----------------------------------

A total of 105 human prevalence studies for DENV were identified from eligible reports ([Table 3](#pntd.0005194.t003){ref-type="table"}). These studies covered 13 of 24 MENA countries and were conducted from 1962--2015. The geographic distribution of these studies is illustrated in [Fig 2](#pntd.0005194.g002){ref-type="fig"}, and [Table 4](#pntd.0005194.t004){ref-type="table"} contains a frequency summary of these studies. Anti-DENV antibodies were detected in 12 of 13 countries in which studies were reported with a single 1973 study from Libya reporting 0% seroprevalence \[[@pntd.0005194.ref035]\]. The highest number of studies were reported from Pakistan (n = 32) and Sudan (n = 16), most of which targeted populations with acute DENV infection (undifferentiated AFI or suspected dengue infection). Among general population studies, IgG prevalence measures ranged from 0% to 61% and were reported from Djibouti (n = 4, 0--21%), Egypt (n = 4, 0--7%), Iran (n = 3, 0--7%), Kuwait (n = 3, 0--56%), Lebanon (n = 3, 0--61%), Pakistan (n = 3, 9--28%), Saudi Arabia (n = 4, 0--33%), and Sudan (n = 5, 9--49%). ELISAs were the most commonly used diagnostic method for all study types and the majority studies from the MENA used in-house assays ([Table 4](#pntd.0005194.t004){ref-type="table"}). VNT results were reported in 3% (n = 3) of all studies while observed or potential serologic cross-reactions with other flaviviruses were present in multiple studies \[[@pntd.0005194.ref036]--[@pntd.0005194.ref038]\] (Tables [3](#pntd.0005194.t003){ref-type="table"} and [4](#pntd.0005194.t004){ref-type="table"}). Three human incidence measures for DENV were identified ([Table 5](#pntd.0005194.t005){ref-type="table"}): the first reported an ELISA IgM incidence of 35 cases per 10,000 people living in urban homes in Port Sudan City, Sudan where DENV-carrying mosquitoes were identified over an 11-month period \[[@pntd.0005194.ref039]\]; the second reported an ELISA IgM incidence of 94 cases per 10,000 people in a general population in Port Sudan, Sudan over a 17-week period in 2010 \[[@pntd.0005194.ref040]\]; the third reported an ELISA IgM, NS1 antigen, or PCR incidence of 185 cases per 100,000 febrile children in an urban slum in Karachi, Pakistan from 1999--2001 \[[@pntd.0005194.ref041]\]. Three vector infection rate studies for *Ae*. *aegypti* and *Ae*. *albopictus* were identified from Pakistan and Yemen \[[@pntd.0005194.ref042], [@pntd.0005194.ref043]\] ([Table 6](#pntd.0005194.t006){ref-type="table"}).

![Geographic distribution of human prevalence studies and reported outbreaks of dengue in the Middle East and North Africa.](pntd.0005194.g002){#pntd.0005194.g002}
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###### Human prevalence studies for dengue virus in the Middle East and North Africa (n = 105).
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  Country, Ref.                              Year(s) of study[\*](#t003fn001){ref-type="table-fn"}   City or governorate                   Setting; population (age range, years)                                                                            Sampling      Assay type             Assay make[^†^](#t003fn002){ref-type="table-fn"}   Target Protein   Assay serotype   Sample size   Prevalence                                         Additional testing& Comments
  ------------------------------------------ ------------------------------------------------------- ------------------------------------- ----------------------------------------------------------------------------------------------------------------- ------------- ---------------------- -------------------------------------------------- ---------------- ---------------- ------------- -------------------------------------------------- ---------------------------------------------------------------------------------------------------------------
  **Afghanistan** (n = 1)                                                                                                                                                                                                                                                                                                                                                                                                                               
   Elyan \[[@pntd.0005194.ref044]\]          2008--10                                                Uruzgon, Helmand, Kandahar            Hospital; AFI patients (20--59)                                                                                   Conv.         ELISA                  PanBio                                             Env              1--4             913           **19.2%**[\*\*](#t003fn003){ref-type="table-fn"}   2.6% (8/312) were IgM+; observed cross-reaction to WNV, TBEV
  **Djibouti** (n = 6)                                                                                                                                                                                                                                                                                                                                                                                                                                  
   Salah \[[@pntd.0005194.ref045]\]          1987                                                    Djibouti City                         Military; healthy soldiers                                                                                        Conv.         IIFA                   In-house                                           wv               2                50            **0%**                                             
                                                                                                     Randa                                 Rural community; general pop.                                                                                     Conv.         IIFA                   In-house                                           wv               2                69            **0%**                                             
                                                                                                     Djibouti City                         Hospital; AFI patients                                                                                            Conv.         IIFA                   In-house                                           wv               2                41            **0%**                                             
  Rodier \[[@pntd.0005194.ref037]\]          1991                                                    Djibouti City                         Clinical setting; AFI patients (1--55)                                                                            Conv.         ELISA IgM              In-house                                           wv               1                91            **7.7%**[\*\*](#t003fn003){ref-type="table-fn"}    3.7% (1/27) were VNT+; multiple observed cross-reactions
                                                                                                                                                                                                                                                             Conv.         ELISA IgM              In-house                                           wv               2                *same*        **25.2%**[\*\*](#t003fn003){ref-type="table-fn"}   11.1% (3/27) were VNT+; multiple observed cross-reactions
                                                                                                                                                                                                                                                             Conv.         ELISA IgM              In-house                                           wv               3                *same*        **16.4%**[\*\*](#t003fn003){ref-type="table-fn"}   multiple observed cross-reactions
                                                                                                                                                                                                                                                             Conv.         ELISA IgM              In-house                                           wv               4                *same*        **18.7%**[\*\*](#t003fn003){ref-type="table-fn"}   multiple observed cross-reactions
   Fauld \[[@pntd.0005194.ref046]\]          2011                                                    Djibouti City                         Animal quarantine station; workers                                                                                Conv.         IIFA                   EuroImmun                                          wv               1--4             10            **10.0%**[\*\*](#t003fn003){ref-type="table-fn"}   not cross-reactive to WNV
   Andayi \[[@pntd.0005194.ref047]\]         2010--11                                                Djibouti City                         Community; general pop. (\<1--100)                                                                                SRS           ELISA                  PanBio                                             Env              1--4             911           **21.8%**                                          
  **Egypt** (n = 5)                                                                                                                                                                                                                                                                                                                                                                                                                                     
   Mohammed \[[@pntd.0005194.ref048]\]       1966                                                    Abyss                                 rural community; general pop.                                                                                     Conv.         HI                     In-house                                           wv               1                29            **7.0%**[\*\*](#t003fn003){ref-type="table-fn"}    possible cross-reaction to WNV
                                                                                                                                                                                                                                                                           HI                     In-house                                           wv               4                *same*        **3.0%**[\*\*](#t003fn003){ref-type="table-fn"}    possible cross-reaction to WNV
                                                                                                     Alexandria                            urban community; general pop.                                                                                     Conv.         HI                     In-house                                           wv               1                55            **4.0%**[\*\*](#t003fn003){ref-type="table-fn"}    possible cross-reaction to WNV
                                                                                                                                                                                                                                                                           HI                     In-house                                           wv               4                *same*        **5.0%**[\*\*](#t003fn003){ref-type="table-fn"}    possible cross-reaction to WNV
   Mohammed \[[@pntd.0005194.ref049]\]       1968                                                    Alexandria                            Hospital; AFI patients (3--13)                                                                                    Conv.         HI, CF                 In-house                                           wv               1                120           **0%**[\*\*](#t003fn003){ref-type="table-fn"}      0% (0/48) were convalescent +
                                                                                                     Alexandria                            Clinical setting; adults                                                                                          Conv.         HI                     In-house                                           wv               1                78            **0%**                                             
   Darwish \[[@pntd.0005194.ref050]\]        1969                                                    Multiple                              University; students                                                                                              Conv.         HI                     In-house                                           wv               1                1133          **0.3%**                                           
  **Iran** (n = 4)                                                                                                                                                                                                                                                                                                                                                                                                                                      
   Saidi \[[@pntd.0005194.ref051]\]          1970                                                    Multiple                              n/s                                                                                                               n/s           HI                     In-house                                           wv               1,2,3            394           **6.0%**[\*\*](#t003fn003){ref-type="table-fn"}    possible cross-reaction to WNV
   Saidi \[[@pntd.0005194.ref052]\]          1970--71                                                Caspian region                        Community; children (1--6)                                                                                        Conv.         HI                     In-house                                           wv               2                100           **0%**                                             
   Chinikar \[[@pntd.0005194.ref053]\]       2000--12                                                Countrywide                           Clinical setting; AFI patients                                                                                    Conv.         ELISA                  Vircell                                            wv               1,2              300           **3.3%**                                           3.3% (10/300) were IgM+; DEN-1,2 were positive by PCR
   Aghaie \[[@pntd.0005194.ref014]\]         2014                                                    Sistan-Baluchestan                    blood donor center; general pop.                                                                                  Conv.         ELISA                  PanBio                                             Env              1--4             540           **7.6%**                                           78% (32/41) ELISA+ were IFA+
  **Kuwait** (n = 8)                                                                                                                                                                                                                                                                                                                                                                                                                                    
   Ibrahim \[[@pntd.0005194.ref054]\]        1966--68                                                Multiple                              Multiple settings; blood donors, non-AFI patients, children (1--60)                                               Conv.         HI                     In-house                                           wv               1                627           **6.5%**[\*\*](#t003fn003){ref-type="table-fn"}    not cross-reactive to DEN-2 or WNV
                                                                                                                                                                                                                                                                           HI                     In-house                                           wv               2                *same*        **8.1%**[\*\*](#t003fn003){ref-type="table-fn"}    not cross-reactive to DEN-1 or WNV
   Al-Nakib \[[@pntd.0005194.ref055]\]       1979--82                                                Jabriya                               Hospital; non-AFI patients (0--60+)                                                                               SRS           HI                     In-house                                           wv               1                502           **3.2%**[\*\*](#t003fn003){ref-type="table-fn"}    not cross-reactive to DEN-2 or WNV
                                                                                                                                                                                                                                                                           HI                     In-house                                           wv               2                *same*        **8.4%**[\*\*](#t003fn003){ref-type="table-fn"}    all were cross-reactive to DEN-1, WNV, or TBEV
   Pacsa \[[@pntd.0005194.ref056]\]          2002[\*](#t003fn001){ref-type="table-fn"}               Multiple                              n/s; Kuwaiti nationals                                                                                            n/s           ELISA and IgG blot     CDC and Genlab                                     wv               1--4             425           **13.9%**                                          only DENV 1--3 were positive
                                                                                                                                           n/s; Kuwait Bedouins                                                                                              n/s           ELISA and IgG blot     CDC and Genlab                                     wv               1--4             47            **0%**                                             
                                                                                                                                           n/s; expatriates from South Asia                                                                                  n/s           ELISA and IgG blot     CDC and Genlab                                     wv               1--4             266           **37%**                                            only DENV 1--3 were positive
                                                                                                                                           n/s; expatriates from Southeast Asia                                                                              n/s           ELISA and IgG blot     CDC and Genlab                                     wv               1--4             31            **56.6%**                                          only DENV 1--3 were positive
                                                                                                                                           n/s; expatriates from Middle East                                                                                 n/s           ELISA and IgG blot     CDC and Genlab                                     wv               1--4             140           **25%**                                            only DENV 1--3 were positive
                                                                                                                                           Hospital; returned travelers with dengue-like illness                                                             n/s           ELISA IgM              PanBio                                             Env              1--4             210           **9.0%**                                           only DENV 1--3 were positive; 10%(2/19) IgM+ were PCR+
  **Lebanon** (n = 3)                                                                                                                                                                                                                                                                                                                                                                                                                                   
   Garabedian \[[@pntd.0005194.ref005]\]     1962--65                                                Multiple                              Community; general pop. (0--41+)                                                                                  SRS           HI                     In-house                                           wv               2                113           **61.9%**[\*\*](#t003fn003){ref-type="table-fn"}   observed cross-reaction with WNV, YFV
                                                                                                     Multiple                              Community; general pop. (0--41+)                                                                                  SRS           HI                     In-house                                           wv               1                171           **49.1%**[\*\*](#t003fn003){ref-type="table-fn"}   observed cross-reaction with WNV, YFV
   Hatem \[[@pntd.0005194.ref057]\]          1969                                                    Beirut                                n/s                                                                                                               n/s           HI                     In-house                                           wv               2                126           **0%**                                             
                                                                                                                                           n/s                                                                                                               n/s           HI                     In-house                                           wv               1                *same*        **4.0%**[\*\*](#t003fn003){ref-type="table-fn"}    observed cross-reaction with WNV
  **Libya** (n = 1)                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Darwish \[[@pntd.0005194.ref035]\]         1973                                                    Sebha                                 community and clinic; children, non-AFI patients                                                                  Conv.         HI                     In-house                                           wv               1                148           **0%**                                             
  **Pakistan** (n = 32)                                                                                                                                                                                                                                                                                                                                                                                                                                 
   Darwish \[[@pntd.0005194.ref031]\]        1983[\*](#t003fn001){ref-type="table-fn"}               Karachi                               Hospital; patients                                                                                                Conv.         CF                     In-house                                           wv               1                43            **9.3%**                                           
   Akram \[[@pntd.0005194.ref058]\]          1994                                                    Karachi                               Hospital; AFI patients (\<1--12)                                                                                  Conv.         ELISA IgM              In-house                                           wv               1                92            **9.8%**[\*\*](#t003fn003){ref-type="table-fn"}    12% (3/25) additional convalescent sera were +; observed cross-reaction to WNV
                                                                                                                                                                                                                                                             Conv.         ELISA IgM              In-house                                           wv               2                *Same*        **14.6%**[\*\*](#t003fn003){ref-type="table-fn"}   24% (6/25) additional convalescent sera were +; observed cross-reaction to WNV
   Siddiqui \[[@pntd.0005194.ref041]\]       1999--2001                                              Karachi                               Community; AFI patients (\<16)                                                                                    Conv.         ELISA IgM              Diag. Auto.                                        wv               1--4             341           **15.8%**                                          
   Tariq \[[@pntd.0005194.ref059]\]          2003                                                    Mangla, Mirpur                        Community; suspected dengue                                                                                       Conv.         ELISA IgM              In-house                                           n/s              n/s              52            **73%**                                            
   Jamil \[[@pntd.0005194.ref060]\]          2005                                                    Karachi                               Hospitals; suspected dengue                                                                                       Conv.         ELISA IgM              Chemicon                                           n/s              n/s              106           **36.8%**                                          
   Khan \[[@pntd.0005194.ref061]\]           2006                                                    Karachi                               Hospital; suspected dengue (2--72)                                                                                Conv.         ELISA IgM              PanBio                                             Env              1--4             83            **83.6%**                                          
                                                                                                                                                                                                                                                             Conv          ELISA IgM              Calbiotech                                         PA               1--4             *same*        **50.7%**                                          87.8% (73/83) were PCR+ for DEN-2,3 only
   Khan \[[@pntd.0005194.ref062]\]           2006                                                    Karachi                               Hospital; suspected dengue                                                                                        Conv.         ELISA                  PanBio                                             Env              1--4             250           **23.2%**                                          53.6% (134/250) were IgM+; 74% (185/250) were PCR+ for DEN-2 or 3
   Koo \[[@pntd.0005194.ref063]\]            2006--11                                                Multiple                              Clinic settings; suspected dengue                                                                                 Conv.         PCR                    In-house                                                            2,3              200           **47%**                                            none were DEN-1 positive
   Khan \[[@pntd.0005194.ref064]\]           2006--07                                                Hyderabad                             Hospital; suspected dengue (13--70)                                                                               Conv.         ELISA IgM              In-house                                           n/s              n/s              50            **40%**                                            
   Khan \[[@pntd.0005194.ref065]\]           2006--07                                                Multiple                              Hospital; suspected dengue                                                                                        Conv.         ELISA IgM              Calbiotech                                         PA               1--4             15,040        **26.3%**                                          
   Abbasi \[[@pntd.0005194.ref066]\]         2007--08                                                Karachi                               Hospital; suspected dengue                                                                                        Conv.         ELISA IgM              Commercial                                         n/s              n/s              114           **69.6%**                                          
   Tahir \[[@pntd.0005194.ref067]\]          2008                                                    Lahore                                Hospital; suspected dengue                                                                                        Conv.         ICT (IgM)              In-house                                           n/s              n/s              3215          **54.9%**                                          
   Murad \[[@pntd.0005194.ref068]\]          2008                                                    Shangla                               Community; suspected dengue (1--80)                                                                               Conv.         ELISA IgM              n/s                                                n/s              n/s              70            **17.1%**                                          
  Mahmood \[[@pntd.0005194.ref069]\]         2008                                                    Lahore                                Hospital; suspected dengue secondary infection (age 1--80)                                                        Conv.         ELISA                  NovaLisa                                           Env              1--4             200           **39.5%**                                          
                                                                                                                                           Hospital; suspected dengue primary infection (age 1--80)                                                          Conv.         ELISA IgM              DRG                                                n/s              2                341           **48.7%**                                          
  Kidwai \[[@pntd.0005194.ref070]\]          2008--09                                                Karachi                               Hospital; suspected dengue (\>13)                                                                                 Conv.         ICT (IgG)              In-house                                           wv               1--4             599           **83.2%**                                          41.9% (251/599) were IgM+
  Zafar \[[@pntd.0005194.ref071]\]           2009                                                    Rawalpindi                            rural communities; adults without history of flavivirus vaccination (\>18)                                        StRS          ELISA                  Omega                                              PA (DEN-2)       1--4             96            **19.8%**                                          
  Zafar \[[@pntd.0005194.ref072]\]           2009                                                    Rawalpindi                            Community; general pop.                                                                                           Conv.         ELISA                  Omega,Vircell                                      PA (DEN-2)       1--4             244           **28.8%**                                          
   Qureshi \[[@pntd.0005194.ref073]\]        2010--12                                                Karachi                               Hospital; suspected dengue                                                                                        Conv.         ICT (IgM)              In-house                                           n/s              n/s              162           **9.9%**                                           
   Khan \[[@pntd.0005194.ref074]\]           2010                                                    Punjab                                Hospital; suspected dengue (4--60)                                                                                Conv.         ELISA IgM              n/s                                                n/s              n/s              125           **54.4%**                                          
   Hasan \[[@pntd.0005194.ref075]\]          2010                                                    Karachi                               Hospital; suspected dengue (\>12)                                                                                 Conv.         ELISA IgM              n/s                                                n/s              n/s              259           **34.8%**                                          
   Umar \[[@pntd.0005194.ref076]\]           2010                                                    Rawalpindi                            Hospital; suspected dengue                                                                                        Conv.         ELISA IgM              n/s                                                n/s              n/s              500           **6.8%**                                           
   Jameel \[[@pntd.0005194.ref077]\]         2010                                                    Lahore                                Hospital; suspected dengue                                                                                        Conv.         ELISA IgM              In-house                                           n/s              n/s              341           **48.7%**                                          
   Naeem \[[@pntd.0005194.ref078]\]          2011                                                    Lahore                                Hospital; suspected dengue (1--10+)                                                                               Conv.         ELISA IgM              n/s                                                n/s              n/s              79            **25.3%**                                          
   Ahmed \[[@pntd.0005194.ref079]\]          2011                                                    Lahore                                Hospital; suspected dengue (13--81)                                                                               Conv.         ELISA IgM              n/s                                                n/s              n/s              640           **43.9%**                                          
   Ijaz \[[@pntd.0005194.ref080]\]           2011                                                    Lahore                                Hospital; suspected dengue (\<15--60+)                                                                            Conv.         ELISA                  n/s                                                n/s              1--4             5,274         **49%**                                            
   Rashid \[[@pntd.0005194.ref081]\]         2011                                                    Lahore                                Hospital; suspected dengue (\<18)                                                                                 Conv.         ELISA                  n/s                                                n/s              n/s              254           **36.6%**                                          53.9% (137/254) were IgM+
   Khan \[[@pntd.0005194.ref082]\]           2011                                                    Lahore                                Hospital; suspected dengue (5--50+)                                                                               Conv.         ELISA                  In-house                                           wv               1--4             50            **72%**                                            30% (30/50) were IgM+; 66% (33/50) were PCR+ for DEN-1,2; 60% (30/50) were cell culture+
   Hasan \[[@pntd.0005194.ref083]\]          2007--13                                                Multiple                              Hospitals; suspected Crimean-Congo Hemorrhagic Fever                                                              Conv.         ELISA IgM              PanBio                                             Env              1--4             168           **33.9%**                                          2.3% (4/168) were PCR+
   Ali \[[@pntd.0005194.ref084]\]            2011                                                    Khyber Pakhtunkhwa                    Clinical settings; suspected dengue (\<10 to \>51)                                                                Conv.         ELISA                  Diag. Auto.                                        wv               1--4             612           **20.2%**                                          31.9% (195/612) were IgM+
   Hisam \[[@pntd.0005194.ref085]\]          2012                                                    Rawalpindi                            Military Hospital; AFI patients                                                                                   PS            ELISA IgM              n/s                                                n/s              n/s              500           **3.2%**                                           
   Assir \[[@pntd.0005194.ref086]\]          2012                                                    Lahore                                Hospital; suspected dengue (12--90)                                                                               Conv.         ELISA IgM              GmbH                                               wv               1--4             85            **43.5%**                                          20% (3/15) were PCR + for DEN-2
  **Saudi Arabia** (n = 11)                                                                                                                                                                                                                                                                                                                                                                                                                             
   Fakeeh \[[@pntd.0005194.ref087]\]         1994--99                                                Jeddah                                Hospitals; suspected dengue (1-\>50)                                                                              Conv.         IIFA, HI               In-house                                           wv               1,2              985           **31.9%**                                          16.2% (160/985) were ELISA IgM+; 21% (207/985) were PCR+ (DEN-1,2,3)
   Fakeeh \[[@pntd.0005194.ref088]\]         1994--2002                                              Jeddah                                Hospitals; suspected dengue                                                                                       Conv.         IFA, HI                In-house                                           wv               1,2,3            1020          **50.5%**                                          10.8% (110/1020) were ELISA IgM+; 20.5% (209/1020) were PCR+ (DEN-1,2,3)
   Khan \[[@pntd.0005194.ref089]\]           2004                                                    Makkah                                Hospital; suspected dengue (6--94)                                                                                              ELISA                  PanBio                                             Env              1--4             136           **32.4%**                                          58.8% (80/136) were IgM+; 28.1% (27/96) were PCR + (DEN-2,3)
   Ayyub \[[@pntd.0005194.ref090]\]          2004--05                                                Jeddah                                Hospital; suspected dengue (2--60)                                                                                Conv.         ELISA IgM              n/s                                                n/s              n/s              80            **48.8%**                                          
   Shahin \[[@pntd.0005194.ref091]\]         2006--08                                                Makkah                                Hospital; suspected dengue                                                                                        Conv.         ELISA IgM and/or PCR   n/s                                                n/s              n/s              159           **100%**                                           
   Said \[[@pntd.0005194.ref092]\]           2006                                                    Jeddah                                Hospital; suspected dengue (2--71)                                                                                Conv.         ELISA IgM              In-house                                           n/s              n/s              525           **19.2%**                                          \% includes paired serum sample
   Memish \[[@pntd.0005194.ref093]\]         2010                                                    Multiple                              Military; adults                                                                                                  Conv.         ELISA                  PanBio                                             Env              1--4             1024          **0.1%**                                           0% of IgG+ were IgM+
   Gamil \[[@pntd.0005194.ref094]\]          2010--11                                                Jeddah                                Hospitals; suspected dengue (3--56)                                                                               Conv.         n/s                    n/s                                                n/s              n/s              553           **47.7%**                                          
   Al-Azraqi \[[@pntd.0005194.ref095]\]      2013                                                    Jizan                                 Clinics; clinic attendants (1--60+)                                                                               SRS           ELISA                  Focus                                              wv               1--4             268           **26.5%**                                          
                                                                                                     Aseer                                 Clinics; clinic attendants (1--60+)                                                                               SRS           ELISA                  Focus                                              wv               1--4             697           **33.7%**                                          
   Ashshi \[[@pntd.0005194.ref096]\]         2014                                                    Mecca                                 blood donation center; adults                                                                                     Conv.         ELISA                  PanBio                                             Env              1--4             100           **7%**                                             6% (6/100) were IgM+;1% (1/100) were NS1+
  **Somalia** (n = 7)                                                                                                                                                                                                                                                                                                                                                                                                                                   
   Botros \[[@pntd.0005194.ref097]\]         1987                                                    Hargeysa                              Refugee camp; AFI patients                                                                                        Conv.         ELISA                  In-house                                           wv               2                38            **60.7%**                                          acute and convalescent samples; 39.4% (15/38) were IFA+; 37.9% (11/29) were HI+; 14.2% (4/28) were ELISA IgM+
  Kanesa-thasan \[[@pntd.0005194.ref098]\]   1993                                                    n/s                                   Military base; AFI soldiers                                                                                       Conv.         ELISA IgM and/or HI    n/s                                                n/s              n/s              84            **17.8%**                                          93% (14/15) were cell culture + (DEN-2 and 3 only)
   Sharp \[[@pntd.0005194.ref099]\]          1992--93                                                Mogadishu                             Military Hospital; AFI patients (soldiers)                                                                        Conv.         ELISA IgM              In-house                                           wv               1--4             129           **34.9%**                                          40.6% (39/96) were cell culture positive for DEN-2; 2% (2/96) were cell culture positive for DEN-3
                                                                                                     Baardera                              Military; adults (19--25)                                                                                         Conv.         ELISA IgM              In-house                                           wv               1--4             494           **7.7%**[\*\*](#t003fn003){ref-type="table-fn"}    observed cross-reaction with WNV
   Nur \[[@pntd.0005194.ref100]\]            1995                                                    Mogadishu                             Hospital; children (\<1 to \> 2 years of age)                                                                     CC\.          ELISA IgM              Progen                                             wv               2                23            **0%**                                             
                                                                                                                                           Hospital; AFI patients with / without rash (\<1 to \> 2 years of age)                                             CC\.          ELISA IgM              Progen                                             wv               2                46            **0%**                                             
   Kyobe Bosa \[[@pntd.0005194.ref101]\]     2011                                                    Mogadishu                             Hospitals; AFI patients (20--49)                                                                                  Conv.         ELISA IgM              n/s                                                n/s              1,2,3            134           **80%**                                            62% (83/134) were PCR+
  **Sudan** (n = 16)                                                                                                                                                                                                                                                                                                                                                                                                                                    
   Omer \[[@pntd.0005194.ref036]\]           1976                                                    Gezira                                Rural community; general pop. (5--40+)                                                                            Conv.         HI                     In-house                                           wv               2                109           **27.5%**                                          17.4% (19/109) were VNT+
   Hyams \[[@pntd.0005194.ref102]\]          1984                                                    Port Sudan                            Hospital; AFI patients (12--70)                                                                                   Conv.         HI                     In-house                                           wv               n/s              100           **3%**                                             14.8% (8/54) were convalescent +; 1% (1/100) DEN-1 cell culture +; 17% (17/100) DEN-2 cell culture +
   Woodruff \[[@pntd.0005194.ref103]\]       1986                                                    Juba                                  Hospital; patients with history of fever within past 6 months and AFI patients (1--85)                            Conv.         HI                     In-house                                           n/s              n/s              130           **40.0%**[\*\*](#t003fn003){ref-type="table-fn"}   represents single virus activity not cross-reactive to multiple flaviviruses tested
   McCarthy \[[@pntd.0005194.ref104]\]       1988                                                    Khartoum                              Clinical setting; non-AFI patients                                                                                CC            ELISA                  In-house                                           wv               2                100           **49%**                                            0% were IgM+
                                                                                                                                           Clinical setting; AFI patients (1--89)                                                                            CC            ELISA                  In-house                                           wv               2                196           **48%**[\*\*](#t003fn003){ref-type="table-fn"}     0% were IgM+; possible cross-reaction to WNV
   Watts \[[@pntd.0005194.ref018]\]          1989                                                    Northern Province                     Clinical setting; AFI patients (11--70)                                                                           Conv.         ELISA                  In-house                                           n/s              2                185           **24.0%**[\*\*](#t003fn003){ref-type="table-fn"}   possible cross-reactions to multiple flaviviruses
   Ibrahim \[[@pntd.0005194.ref105]\]        1997--99                                                Khartoum                              Clinical setting: suspected measles                                                                               Conv.         ELISA IgM              MRL Diag.                                          n/s              n/s              188           **3.2%**                                           
   Malik \[[@pntd.0005194.ref106]\]          2004--05                                                Port Sudan                            Hospitals; suspected dengue (\<1--15)                                                                             Conv.         ELISA IgM              PanBio                                             Env              1--4             40            **90.0%**                                          39% (9/23) were PCR+ (DEN-3)
   Gould \[[@pntd.0005194.ref107]\]          2005                                                    South Kordofan                        Clinical setting; suspected YF patients (n = 3), severe illness (n = 8), AFI patients (n = 7), healthy (n = 16)   Conv.         ELISA IgM              In-house                                           wv               n/s              34            **5.9%**[\*\*](#t003fn003){ref-type="table-fn"}    observed cross-reaction with YFV, WNV
   Farnon \[[@pntd.0005194.ref038]\]         2005                                                    Kortalla                              Community; general pop., YF vaccinated (0--44+)                                                                   SSCS          ELISA                  In-house                                           wv               1--4             87            **1.1%**[\*\*](#t003fn003){ref-type="table-fn"}    observed cross-reaction in YF vaccine recipient; 0% were IgM+; 52% (45/87) were VNT+ for DENV and YFV
   Seidahmed \[[@pntd.0005194.ref039]\]      2008--09                                                Port Sudan City                       Urban community; individuals from houses with DENV-carrying mosquitoes (\<1--80)                                  RSS           ELISA IgM              PanBio                                             Env              1--4             791           **5.2%**                                           
   Adam \[[@pntd.0005194.ref108]\]           2008--09                                                Port Sudan City                       Hospitals; pregnant women with deliveries                                                                         Ret. cohort   ELISA IgM              n/s                                                n/s              1--4             10,820        **0.7%**                                           
   Himatt \[[@pntd.0005194.ref109]\]         2011                                                    Kassala state                         Community; general pop. (5--75+)                                                                                  MSCS          ELISA                  PanBio                                             Env              1--4             489           **9.4%**                                           0.6% (3/489) were IgM+
   Abdalla \[[@pntd.0005194.ref110]\]        2012                                                    Kassala State                         Hospital; AFI patients with suspected measles (2--65)                                                             Conv.         ELISA                  PanBio                                             Env              1--4             60            **11.7%**                                          
   Elduma \[[@pntd.0005194.ref015]\]         2012                                                    Port Sudan                            Hospital; pregnant women with AFI                                                                                 Conv.         ELISA                  Commercial                                         n/s              n/s              39            **12.8%**                                          2.6% (1/39) were IgM+ and PCR+
   Soghaier \[[@pntd.0005194.ref111]\]       2014                                                    South Kordofan                        Urban and rural communities; general pop. (15--60)                                                                MSCS          ELISA                  PanBio                                             Env              1--4             600           **27.7%**                                          77% of study population were YFV vaccinated
  **Turkey** (n = 6)                                                                                                                                                                                                                                                                                                                                                                                                                                    
   Ari \[[@pntd.0005194.ref034]\]            1971                                                    Izmir                                 Community and clinic; general pop.                                                                                Conv.         HI                     In-house                                           wv               2                270           **0%**                                             
   Radda \[[@pntd.0005194.ref112]\]          1973[\*](#t003fn001){ref-type="table-fn"}               Izmir                                 n/s; general pop.                                                                                                 Conv.         HI                     In-house                                           wv               2                270           **0.3%**[\*\*](#t003fn003){ref-type="table-fn"}    observed cross-reaction with WNV
                                                                                                     Istanbul                              n/s; general pop.                                                                                                 Conv.         HI                     In-house                                           wv               2                90            **0%**                                             
                                                                                                     Ankara                                n/s; general pop.                                                                                                 Conv.         HI                     In-house                                           wv               2                95            **0%**                                             
   Ergunay \[[@pntd.0005194.ref113]\]        2010                                                    Ankara, Konya, Eskisehir, Zonguldak   blood donation center; blood donors                                                                               Conv.         ELISA                  EuroImmun                                          wv               1--4             2435          **0.9%**                                           14.2% (3/21) of IgG+ were IIFT+ for DEN-2; 9.5% (2/21) of IgG+ were IgM+
   Tezcan \[[@pntd.0005194.ref114]\]         2010--11                                                Mersin                                blood donation center; blood donors                                                                               Conv.         ELISA                  Vircell                                            wv               1--4             920           **16.6%**                                          0.9% (8/920) were IgM+; 0% were NS1+
  **Yemen** (n = 5)                                                                                                                                                                                                                                                                                                                                                                                                                                     
   Bin Ghouth \[[@pntd.0005194.ref115]\]     2011                                                    Hadramout                             Hospital; suspected dengue (\<5 to 55+)                                                                           Conv.         ELISA                  PanBio                                             Env              1--4             982           **50.6%**                                          64.1% (630/982) IgM+; 86.2% (163/189) PCR+ for DEN-3
   Malik \[[@pntd.0005194.ref116]\]          2010--11                                                Al-Hudaydah                           Clinical setting; AFI patients (0--45+)                                                                           Conv.         ELISA                  PanBio                                             Env              1--4             136           **87.5%**                                          8.1% (11/136) were IgM+
   Madani \[[@pntd.0005194.ref117]\]         2010                                                    Hadramout                             Clinical settings; suspected viral hemorrhagic fever (3--75)                                                      Conv.         ELISA                  PanBio                                             Env              1--4             207           **48.3%**                                          78.7% (163/207) IgM+; 46.9% (97/207) NS1+; 0.09% (2/207) PCR+ for DEN-1,2
   Rezza \[[@pntd.0005194.ref118]\]          2012                                                    Al Hudaydah                           Hospitals; AFI patients with dengue-like illness (1--60)                                                          CS            ELISA                  NovaLisa                                           Env              1--4             400           **72.5%**                                          18% (72/400) IgM+; 13.8% (55/400) PCR+ for DEN-1,2
   Qassem \[[@pntd.0005194.ref119]\]         2013                                                    Hadramout                             Clinical setting; suspected dengue and/or west nile infection                                                     Conv.         ELISA IgM              n/s                                                n/s              n/s              42            **19.0%**[\*\*](#t003fn003){ref-type="table-fn"}   observed cross-reaction with WNV

\* Indicates year of publication when year(s) of data collection not available in report.

^**†**^ All serologic assays were IgG unless otherwise stated.

\*\*Indicates documented occurrence or suspicion of false-positives due to cross-reactions with other same family viruses or low serologic titers.

Abbreviations: AFI, acute febrile illness patients; Ag, antigen; CF, complement fixation; Conv, convenience; ELISA, enzyme-linked immunosorbent assay; HI, hemagglutinin inhibition; ICT, immunochromatography test; IIFA, indirect immunofluorescence antibody test; MSCS, multi-stage cluster sampling; n/s, not specified; NS1, NS1 antigen test; PA, purified antigen; PCR, polymerase chain reaction; pop., population; PS, purposive sampling; RSS, random stratified sampling; SRS, simple random sampling; SSCS, single stage cluster sampling; VNT, viral neutralization test

Assay Abbreviation: *CDC* (Centers for Disease Control and Prevention, USA); *Chemicon* (Chemicon, Temecula, CA, USA); *Diag*. *Auto*. (Diagnostic Automation, CA, USA); *DRG* (DRG International Inc); *Euroimmun* (Lubeck, Germany); *Focus* (Focus Diagnostics, Cypress CA, USA); Genlab (Genlab Diagnostics, Singapore); GmbH (Human GmbH, Wiesbaden, Germany); *MRL Diagnostics* (Cypress CA, USA); *NovaLisa* (Dietzenbach, Germany); *Omega* (Omega Diagnostics, Scotland, UK); *PanBio* (Brisbane, Australia); *Progen* (Heidelberg, Germany); *SD Bioline* (Standard Diagnostics, Korea); *Vircell* (Vircell Microbiologists, Granada, Spain)

10.1371/journal.pntd.0005194.t004

###### Summary of human prevalence studies for dengue virus in the Middle East and North Africa (n = 103).[\*](#t004fn001){ref-type="table-fn"}
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  **Study characteristics**                               **General population (n = 42) n (%)**                **Acute febrile illness (n = 23) n (%)**   **Suspected dengue (n = 38) n (%)**
  ------------------------------------------------------- ---------------------------------------------------- ------------------------------------------ -------------------------------------
  Total sample size                                       24,377                                               4,065                                      33,955
  Median DENV % prevalence (range %)                      25% (0--61.9)                                        15.2% (0--87.5)                            47.4% (6.8--100)
  Year of study                                                                                                                                           
    before 1990                                           21 (50%)                                             7 (30%)                                    0
    1990 to 2015                                          21 (50%)                                             16 (70%)                                   38 (100%)
  Study setting                                                                                                                                           
    community                                             31 (74%)[^**†**^](#t004fn002){ref-type="table-fn"}   2 (9%)                                     2 (5%)
    clinic or hospital                                    11 (26%)                                             21 (91%)                                   36 (95%)
  Assay                                                                                                                                                   
    ELISA IgG                                             19 (45%)                                             8 (35%)                                    10 (26%)
    ELISA IgM                                             11 (26%)                                             17 (74%)                                   31 (82%)
    immunofluorescence antibody                           5 (12%)                                              2 (9%)                                     2 (5%)
    hemagglutination inhibition                           15 (36%)                                             5 (22%)                                    2 (5%)
    complement fixation                                   1 (2%)                                               1 (4%)                                     0
    viral neutralization                                  2 (5%)                                               1 (4%)                                     0
    PCR                                                   0                                                    4 (17%)                                    14 (37%)
    cell culture                                          0                                                    3 (13%)                                    1 (3%)
    NS1 antigen                                           2 (5%)                                               0                                          1 (3%)
  Assay make                                                                                                                                              
    in-house                                              21 (50%)                                             10 (43%)                                   11 (29%)
    commercial                                            20 (48%)                                             10 (43%)                                   15 (39%)
    not specified                                         1 (2%)                                               3 (13%)                                    12 (32%)
  Target protein[\*\*](#t004fn003){ref-type="table-fn"}                                                                                                   
    whole virus                                           32 (76%)                                             12 (52%)                                   6 (16%)
    envelope                                              7 (17%)                                              4 (17%)                                    9 (24%)
    not specified                                         3 (7%)                                               7 (30%)                                    21 (55%)
  **Risk of bias summary**                                                                                                                                
  Assay                                                                                                                                                   
    low risk of bias                                      2 (5%)                                               8 (35%)                                    14 (37%)
    high risk of bias                                     40 (95%)                                             15 (65%)                                   24 (63%)
    unclear risk of bias                                  0                                                    0                                          1 (3%)
  Sampling methodology                                                                                                                                    
    low risk of bias                                      15 (36%)                                             n/a                                        n/a
    high risk of bias                                     17 (40%)                                             n/a                                        n/a
    unclear risk of bias                                  10 (24%)                                             n/a                                        n/a
  Response rate                                                                                                                                           
    low risk of bias                                      6 (14%)                                              11 (48%)                                   22 (58%)
    high risk of bias                                     1 (3%)                                               0                                          0
    unclear risk of bias                                  35 (83%)                                             12 (52%)                                   16 (42%)
  Precision                                                                                                                                               
    High                                                  28 (67%)                                             15 (65%)                                   28 (74%)
    Low                                                   14 (33%)                                             8 (35%)                                    10 (26%)

\* N = 103 because the study type (i.e. general prevalence, acute febrile illness, or suspected dengue) was not specified in two studies \[[@pntd.0005194.ref051], [@pntd.0005194.ref057]\].

^**†**^Community study settings also include animal quarantine station (n = 1), blood donation center (n = 5), military (n = 3), and university (n = 1).

\*\* Indicates the target protein for the initial screening assay for studies in which multiple diagnostic assays were utilized.

10.1371/journal.pntd.0005194.t005

###### Summary of human incidence studies for dengue virus in the Middle East and North Africa (n = 3).

![](pntd.0005194.t005){#pntd.0005194.t005g}

  Country, Ref.                          Year(s) of study   Duration of follow-up   City or governorate   Setting; population(age range, years)                                                                  Study design   Sampling              Assay type            Assay make^+^   Assay Target   Serotype tested   Sample size                                   Incidence
  -------------------------------------- ------------------ ----------------------- --------------------- ------------------------------------------------------------------------------------------------------ -------------- --------------------- --------------------- --------------- -------------- ----------------- --------------------------------------------- -----------------
  **Pakistan** (n = 1)                                                                                                                                                                                                                                                                                                                                                     
  Siddiqui \[[@pntd.0005194.ref041]\]    1999--2001         1999--2001              Karachi               Urban slum; children \<16 years of age with undifferentiated febrile illness                           CS             Active surveillance   ELISA IgM             Diag. Auto.     wv             1--4              1,248                                         **185/100,000**
  **Sudan** (n = 2)                                                                                                                                                                                                                                                                                                                                                        
  Seidahmed \[[@pntd.0005194.ref039]\]   2008--09           12 months               Port Sudan City       Urban community; general pop. living in houses where DENV-carrying mosquitoes were present (\<1--80)   Pros. coh      RSS                   ELISA IgM             PanBio          Env            1--4              791                                           **35/10,000**
  Seidahmed \[[@pntd.0005194.ref040]\]   2010               17 weeks                Port Sudan            Urban community; general pop.                                                                          CS             Conv.                 ELISA IgM, NS1, PCR   n/s             n/s            n/s               3,765[^‡^](#t005fn001){ref-type="table-fn"}   **94/10,000**

^‡^ Reported cases

Abbreviations: CS, cross-sectional; ELISA, enzyme-linked immunosorbent assay; Env, envelope; PCR, polymerase chain reaction; Pros. coh, prospective cohort; RSS, random stratified sampling

Assay Abbreviation: *Diag*. *Auto*. (Diagnostic Automation, CA, USA); *PanBio* (Brisbane, Australia)

10.1371/journal.pntd.0005194.t006

###### Summary of vector infection rate studies for dengue virus in the Middle East and North Africa (n = 3)
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  Author, Ref.                       Year(s) of data collection   City or governorate   Setting                                          Mosquito species     Assay type         Sample size                      Infection rate   Comments
  ---------------------------------- ---------------------------- --------------------- ------------------------------------------------ -------------------- ------------------ -------------------------------- ---------------- -------------------------------------------------------------
  **Pakistan**                                                                                                                                                                                                                     
  Jahan \[[@pntd.0005194.ref042]\]   2011                         Lahore                Urban areas                                      *Ae*. *aegypti*      Ag-capture ELISA   114 pools (n = 570 mosquitoes)   **27.2%**        
                                                                                                                                         *Ae*. *albopictus*   Ag-capture ELISA   4 pools (n = 20 mosquitoes)      **25%**          
  **Yemen**                                                                                                                                                                                                                        
  Zayed \[[@pntd.0005194.ref043]\]   2010--11                     Al Hodayda            houses of CHIKV cases at Eritrean refugee camp   *Ae*. *aegypti*      RT-PCR             11 pools (n = 30 mosquitoes)     **0%**           17 *Culex spp*. mosquitoes were also negative for DENV RNA.

Abbreviations: RT-PCR, reverse transcription-polymerase chain reaction

Risk of bias assessment results {#sec017}
-------------------------------

The quality assessment for each study is found in [S1 Table](#pntd.0005194.s003){ref-type="supplementary-material"} and a summary of the precision and risk of bias assessment is found in [Table 4](#pntd.0005194.t004){ref-type="table"}. In brief, most studies (≥65%) contained high precision as defined by a sample size of ≥100 participants. A minority (36%) of general population seroprevalence studies utilized some form of random sampling, and response rates were either \<80% or not reported in 86% of general population studies. VNT or a biologic confirmatory assay (i.e. cell culture, PCR, and NS1 ELISA) was performed in 5% and 36% of general population seroprevalence and acute DENV infection studies, respectively, entailing low ROB for the assays used.

Dengue outbreaks and *Aedes* occurrence {#sec018}
---------------------------------------

Reported outbreaks of DENV in the region were gathered through citations collected from the search databases ([S2 Table](#pntd.0005194.s004){ref-type="supplementary-material"}) and mapped along with the geographic distribution of prevalence studies in [Fig 2](#pntd.0005194.g002){ref-type="fig"}. For DENV, 81 outbreaks were reported from 9 countries in the region from 1941--2015, including sentinel reports of autochthonous transmission in Egypt (2010) and Yemen (1983). Reports contained variable descriptions of outbreaks including 'estimated', 'suspected', 'reported', and/or laboratory 'confirmed' cases ([S2 Table](#pntd.0005194.s004){ref-type="supplementary-material"}). The definition that qualified each event as an outbreak was unclear in most instances. Outbreaks of DENV serotypes 1--3 were reported from countries surrounding the Red Sea and DENV-4 was only reported from Pakistan \[[@pntd.0005194.ref120], [@pntd.0005194.ref121]\]. Although, in general, DENV serotypes were not reported consistently.

Published reports of *Ae*. *aegypti and Ae*. *albopictus* occurrence are recorded in [S3 Table](#pntd.0005194.s005){ref-type="supplementary-material"} and mapped by country in [Fig 3](#pntd.0005194.g003){ref-type="fig"}. *Ae*. *aegypti* occurrence was reported in 11 MENA countries and historically (i.e. prior to 1960) in Algeria, Libya, Morocco, Syria, and Tunisia. *Ae*. *albopictus* was reported in seven MENA countries, including Algeria, Palestine, and Syria, countries where *Ae*. *aegypti* is not currently reported. No published reports of *Ae*. *aegypti* or *Ae*. *albopictus* occurrence (or DENV outbreaks) were identified in seven MENA countries: Bahrain, Iran, Iraq, Jordan, Kuwait, Qatar, and United Arab Emirates. Since 2005, *Ae*. *aegypti* and/or *Ae*. *albopictus* occurrence has been documented in Afghanistan, Algeria, Lebanon, Oman, Palestine, Syria, and Turkey, though autochthonous transmission of DENV has not yet been reported from these countries.

![Country-level distribution of *Aedes aegypti* and *Aedes albopictus* occurrence in the Middle East and North Africa.](pntd.0005194.g003){#pntd.0005194.g003}

Discussion {#sec019}
==========

Our study offers an assessment of published prevalence, incidence, and outbreak reports pertaining to the epidemiology of dengue in the MENA region. Based on the study results, the MENA contains two apparent subregions known to harbor DENV: 1) Pakistan, and 2) the Red Sea countries (Djibouti, Egypt, Saudi Arabia, Somalia, Sudan, and Yemen). No seroprevalence or outbreak data was identified across broad areas of the MENA, however, including some *Aedes* endemic areas. There was also a paucity of reports estimating human incidence and vector infection rates. These findings suggest priorities for future research. However, they also challenge efforts to synthesize and compare the inter- and intra-country epidemiology of DENV in the region.

Dengue seroprevalence in the MENA {#sec020}
---------------------------------

In our review, Pakistan reported the highest number of prevalence studies and the broadest study coverage among MENA countries. Multiple studies reported \>20% prevalence in both general population and those with undifferentiated AFI \[[@pntd.0005194.ref001], [@pntd.0005194.ref106], [@pntd.0005194.ref122]--[@pntd.0005194.ref124]\]. DENV serotypes 1--4 are known to circulate in Pakistan, unlike other MENA countries \[[@pntd.0005194.ref082]\]. Pakistan also reported the largest number of confirmed cases among all DENV outbreaks in the MENA, with 21,580 cases reported during the 2011 DENV-2 outbreak \[[@pntd.0005194.ref079], [@pntd.0005194.ref120]\] ([S2 Table](#pntd.0005194.s004){ref-type="supplementary-material"}).

In the Red Sea region, multiple general population and AFI population IgG seroprevalence measures exceeding 20% were published from in Djibouti, Saudi Arabia, Somalia, Sudan, and Yemen within the past decade ([Table 3](#pntd.0005194.t003){ref-type="table"}) along with multiple confirmed outbreaks of DENV serotypes 1--3 since the 1980s ([S2 Table](#pntd.0005194.s004){ref-type="supplementary-material"}). DENV-4 has not yet been identified in this subregion to our knowledge. Although reported outbreaks and cases often localize along the Red Sea coastline in these countries \[[@pntd.0005194.ref001]\], seroprevalence studies suggest a broader distribution of DENV infections that are likely underdetected ([Fig 2](#pntd.0005194.g002){ref-type="fig"}). This is illustrated by the sentinel report of a DENV-infected traveler returning from Yemen in 1983 \[[@pntd.0005194.ref125]\], despite the first outbreaks of DENV in Yemen and Saudi Arabia not being reported until 1994 \[[@pntd.0005194.ref126]--[@pntd.0005194.ref128]\]. Our search also identified no published prevalence studies or outbreaks in Egypt after 1969 until a dengue outbreak was reported in November 2015 \[[@pntd.0005194.ref010]\]. However, DENV transmission was suggested years prior by a report of two travelers diagnosed with dengue after returning from southern Egypt in 2011 \[[@pntd.0005194.ref129]\] and the identification of *Ae*. *aegypti* in southern Egypt that same year \[[@pntd.0005194.ref130]\]. It is plausible that undetected DENV transmission had been occurring in Egypt prior to this outbreak. However, it is not clear whether this and other recent outbreaks represent increasing incidence, increasing detection, or both, amidst the heterogeneity in study coverage and reporting in the MENA.

Clinical and methodological diversity among studies {#sec021}
---------------------------------------------------

An important finding in our study was the clinical and methodological diversity among DENV prevalence studies. This diversity represents a challenge to synthesizing the epidemiologic literature for DENV in the MENA. Clinically, studies represented a diversity of human populations of different ages and demographics, in different years, and different locations and transmission contexts. Ninety-six percent of studies from Afghanistan, Pakistan, Saudi Arabia, Somalia, and Yemen were conducted during or prior to 1990. However, 53% of studies in other MENA countries were conducted prior to 1990, when study methods and DENV epidemiology may have been different. Methodologically, most studies utilized convenience samples without reporting response rates, entailing high risk of bias and uncertainty in the representativeness of reported measures ([Table 4](#pntd.0005194.t004){ref-type="table"}). These findings, along with the high variability in regional study coverage, precluded meta-analyses of the available data.

Flavivirus cross-reactivity {#sec022}
---------------------------

Serologic cross-reactions remain a challenge to seroepidemiologic studies for DENV and other flaviviruses. Viral neutralization tests, considered the gold standard serologic assay for DENV, were performed in only 5% of general population seroprevalence studies in our review. Compared to ELISAs, seroprevalence measures were 22--86% lower by secondary/confirmatory testing with immunofluorescence or VNT in our review \[[@pntd.0005194.ref014], [@pntd.0005194.ref036], [@pntd.0005194.ref037], [@pntd.0005194.ref113]\]. This illustrates the potential uncertainty surrounding the reliability of ELISAs in DENV serologic studies, particularly in areas where the prevalence of antigenically similar viruses is broad or unknown. West Nile virus (WNV), for example, is thought to be distributed across the MENA on account of its ubiquitous *Culex spp*. vector and migratory bird flyways \[[@pntd.0005194.ref131]--[@pntd.0005194.ref133]\]. With up to 80% of WNV infections occurring subclinically, the potential for serologic cross-reactions with DENV antibody assays must be considered. Yellow fever vaccine-derived and natural antibodies may also cross-react with anti-DENV antibodies, especially relevant in YFV endemic regions such as Sudan \[[@pntd.0005194.ref038], [@pntd.0005194.ref107], [@pntd.0005194.ref111]\]. As the emergence of zika virus in the Western Hemisphere or the re-emergence of YFV has shown, serologic assays with low specificity are inadequate to tackle the epidemiologic challenges of emerging arboviral diseases \[[@pntd.0005194.ref134]\].

Heterogeneity in dengue outbreak reports {#sec023}
----------------------------------------

Our review identified DENV outbreaks in over a third of MENA countries, with most outbreaks reported from Pakistan, Sudan, and Saudi Arabia ([S2 Table](#pntd.0005194.s004){ref-type="supplementary-material"}). Outbreaks varied widely across time and space in the MENA: reported cases varied from \<10 to \>100,000 over a span of months to years, reported from the village level to the level of the province and region. This presents a challenge to epidemiologic monitoring and policy planning for DENV, as use of different outbreak definitions results in differences in early detection and response \[[@pntd.0005194.ref030]\]. There is currently no consensus on how to define DENV outbreaks, and adopting a common definition for the MENA is challenging given the region's heterogeneous infection pressures, multiple DENV serotypes, and variable surveillance and detection capacity. At present, assessing whether a reported transmission event in the MENA significantly deviates from baseline transmission, and thus constitutes an outbreak, is often unclear.

Risk factors and research priorities {#sec024}
------------------------------------

Our study did not identify confirmed DENV transmission in any of the MENA countries west of Egypt and east of Saudi Arabia until Pakistan ([Fig 2](#pntd.0005194.g002){ref-type="fig"}). However, the paucity of published data in these sub-regions does not preclude the possibility of unrecognized transmission in some areas or the risk of emergence in others. Indeed, modeling studies suggest ecologic niches for *Aedes* along the coastal Mediterranean Basin of North Africa \[[@pntd.0005194.ref001], [@pntd.0005194.ref123], [@pntd.0005194.ref135]\], and *Ae*. *albopictus* and/or *Ae*. *aegypti* has been recently reported in Algeria, Lebanon, Palestine, Syria, and Turkey \[[@pntd.0005194.ref005], [@pntd.0005194.ref136]--[@pntd.0005194.ref140]\] ([Fig 3](#pntd.0005194.g003){ref-type="fig"} and [S3 Table](#pntd.0005194.s005){ref-type="supplementary-material"}). In contrast, *Ae*. *albopictus* has been identified along the Mediterranean coast of Europe for decades along with local transmission of DENV and chikungunya since 2007 \[[@pntd.0005194.ref141]\]. Near the Pakistan border, serologic evidence suggests possible DENV transmission in Iran \[[@pntd.0005194.ref014], [@pntd.0005194.ref051], [@pntd.0005194.ref053]\] and Afghanistan \[[@pntd.0005194.ref044]\], though local transmission has not been confirmed to our knowledge \[[@pntd.0005194.ref053]\]. The presence of *Aedes* or DENV transmission in these areas should not be ruled out \[[@pntd.0005194.ref053]\].

Several ecologic and social factors in the MENA may promote the spread of *Aedes-*borne viruses like DENV. Urbanization \[[@pntd.0005194.ref142]\] may increase the risk of outbreaks and use of open water storage containers that promote *Ae*. *aegypti* breeding \[[@pntd.0005194.ref001], [@pntd.0005194.ref039], [@pntd.0005194.ref043], [@pntd.0005194.ref055], [@pntd.0005194.ref095], [@pntd.0005194.ref111], [@pntd.0005194.ref123], [@pntd.0005194.ref135]\]. Heavy rainfall has been implicated in DENV outbreaks in Sudan, Djibouti, and Yemen \[[@pntd.0005194.ref012], [@pntd.0005194.ref047], [@pntd.0005194.ref143], [@pntd.0005194.ref144]\], which may become increasingly unpredictable through climate change \[[@pntd.0005194.ref145]\]. Armed conflicts and economic turmoil in Iraq, Syria, and Yemen may render these areas vulnerable to vector-borne diseases while diminishing surveillance and response \[[@pntd.0005194.ref146]\]. Inter-regional migration poses risk for imported DENV, as millions of migrants travel from DENV-endemic countries to the Arabian Peninsula \[[@pntd.0005194.ref111], [@pntd.0005194.ref126], [@pntd.0005194.ref146]--[@pntd.0005194.ref149]\] and to Mecca, Saudi Arabia to attend Umra and Hajj \[[@pntd.0005194.ref126]\]. Intra-regionally, heavy commerce in the Red Sea region likely drives DENV serotype mixing and spread \[[@pntd.0005194.ref116], [@pntd.0005194.ref148]\], as evidenced by multiple DENV outbreaks occurring at port cities in Djibouti \[[@pntd.0005194.ref037], [@pntd.0005194.ref045]\], Saudi Arabia \[[@pntd.0005194.ref126]\], Sudan \[[@pntd.0005194.ref039]\], and Yemen \[[@pntd.0005194.ref116], [@pntd.0005194.ref148]\]. Contiguous spread of DENV from Yemen to Oman \[[@pntd.0005194.ref150]\], or from Pakistan to Iran or Afghanistan \[[@pntd.0005194.ref014]\], may also pose risk.

A number of research priorities emerge concerning the epidemiology of DENV in the MENA. First, broader seroepidemiologic coverage in the region is needed. Such studies are efficient means of characterizing infection pressures in populations lacking surveillance and diagnostic capacity. Multiplexed diagnostics are increasingly available and are well-suited for concurrently exploring the distribution other undercharacterized arboviruses in the region (e.g. Alkhumra, Chikungunya, Crimean-Congo Hemorrhagic Fever, O'Nyong-nyong, Rift Valley Fever, Sandfly Fever virus complex, Usutu, and West Nile viruses). Second, serologic studies should include methods to minimize cross-reactions, particularly for flaviviruses \[[@pntd.0005194.ref151]\]. Third, seroepidemiologic studies should incorporate uniformity in study design and enrollment criteria to minimize confounding, such as standard case definitions for studies of 'suspected' dengue \[[@pntd.0005194.ref126]\]. Ideally this could include population-based sampling that provides baseline data to benchmark the regional impact of these pathogens over the coming years. Fourth, studies should incorporate vector surveillance and infection rates. Such studies are important for understanding transmission dynamics that inform vector control strategies and predict future transmission and disease risk \[[@pntd.0005194.ref123], [@pntd.0005194.ref135], [@pntd.0005194.ref141]\]. Guidelines and tools for calculating vector infection rates are available \[[@pntd.0005194.ref141], [@pntd.0005194.ref152]\]. Finally, attaining a meaningful definition of DENV outbreaks in the MENA countries will require a thorough assessment of baseline surveillance, control, and treatment capacities in endemic regions \[[@pntd.0005194.ref030]\].

Study limitations {#sec025}
-----------------

Our study was limited by its reliance on select databases of peer-reviewed literature screened by one investigator with the exclusion of grey literature which may have provided additional data. Reviewing other *Aedes*-transmitted pathogens or studies reporting *Aedes* distribution in the MENA may also have provided further insights regarding the potential geographic distribution of DENV. Due to the limitations in the content and distribution of studies, we did not perform a meta-analysis nor did we explore bias in overall outcome measures through a funnel plot or Egger test. Non-publication of studies with small or zero effect size or studies targeted to known dengue-endemic areas may have biased the distribution and quantity of DENV studies. The prevalence measures themselves may have been biased through serologic-cross reactions, targeting of older study populations (with higher seroprevalence), and lack of convalescent titers for acute DENV infection studies (possibly underestimating seroprevalence).

Conclusions {#sec026}
===========

DENV seroprevalence in the MENA is high among some populations in the Red Sea region and Pakistan, while recent outbreaks in these subregions suggest increasing DENV incidence driven by ecologic and social factors. Published prevalence and incidence, vector occurrence, and vector infection rates are lacking in broad areas of the MENA and available studies contain methodological limitations. These findings illustrate the need to strengthen programs for surveillance, reporting, and control of DENV and *Aedes* in the MENA, both to define DENV and *Aedes* epidemiology and to mitigate the risk of emerging *Aedes*-transmitted pathogens in the future.
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